GSS Stock Overview
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa.
Genetic Signatures Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.07|
|52 Week High||AU$1.86|
|52 Week Low||AU$0.94|
|1 Month Change||6.50%|
|3 Month Change||-19.62%|
|1 Year Change||-17.44%|
|3 Year Change||1.43%|
|5 Year Change||159.76%|
|Change since IPO||119.59%|
Recent News & Updates
|GSS||AU Life Sciences||AU Market|
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned -31.8% over the past year.
Return vs Market: GSS underperformed the Australian Market which returned -6.5% over the past year.
|GSS Average Weekly Movement||9.5%|
|Life Sciences Industry Average Movement||12.3%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.9%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: GSS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: GSS's weekly volatility (10%) has been stable over the past year.
About the Company
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens.
Genetic Signatures Fundamentals Summary
|GSS fundamental statistics|
Is GSS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GSS income statement (TTM)|
|Cost of Revenue||AU$12.40m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.014|
|Net Profit Margin||6.25%|
How did GSS perform over the long term?See historical performance and comparison
Is GSS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GSS?
Other financial metrics that can be useful for relative valuation.
|What is GSS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does GSS's PE Ratio compare to its peers?
|GSS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
EZZ EZZ Life Science Holdings
VLS Vita Life Sciences
GSS Genetic Signatures
Price-To-Earnings vs Peers: GSS is expensive based on its Price-To-Earnings Ratio (78x) compared to the peer average (20.6x).
Price to Earnings Ratio vs Industry
How does GSS's PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: GSS is expensive based on its Price-To-Earnings Ratio (78x) compared to the Global Life Sciences industry average (36.8x)
Price to Earnings Ratio vs Fair Ratio
What is GSS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||78x|
|Fair PE Ratio||7.7x|
Price-To-Earnings vs Fair Ratio: GSS is expensive based on its Price-To-Earnings Ratio (78x) compared to the estimated Fair Price-To-Earnings Ratio (7.7x).
Share Price vs Fair Value
What is the Fair Price of GSS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GSS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GSS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Genetic Signatures forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSS's earnings are forecast to decline over the next 3 years (-86.6% per year).
Earnings vs Market: GSS's earnings are forecast to decline over the next 3 years (-86.6% per year).
High Growth Earnings: GSS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: GSS's revenue is expected to decline over the next 3 years (-10.6% per year).
High Growth Revenue: GSS's revenue is forecast to decline over the next 3 years (-10.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSS is forecast to be unprofitable in 3 years.
Discover growth companies
How has Genetic Signatures performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSS has high quality earnings.
Growing Profit Margin: GSS's current net profit margins (6.2%) are lower than last year (16.4%).
Past Earnings Growth Analysis
Earnings Trend: GSS has become profitable over the past 5 years, growing earnings by 42.1% per year.
Accelerating Growth: GSS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GSS had negative earnings growth (-58.8%) over the past year, making it difficult to compare to the Life Sciences industry average (29.6%).
Return on Equity
High ROE: GSS's Return on Equity (3.6%) is considered low.
Discover strong past performing companies
How is Genetic Signatures's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GSS's short term assets (A$52.4M) exceed its short term liabilities (A$3.9M).
Long Term Liabilities: GSS's short term assets (A$52.4M) exceed its long term liabilities (A$33.0K).
Debt to Equity History and Analysis
Debt Level: GSS is debt free.
Reducing Debt: GSS has not had any debt for past 5 years.
Debt Coverage: GSS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GSS has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Genetic Signatures's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GSS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GSS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Principal Advisor. Dr. Melki has been...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD439.66K) is above average for companies of similar size in the Australian market ($USD285.38K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: GSS's management team is seasoned and experienced (8.6 years average tenure).
Experienced Board: GSS's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genetic Signatures Limited's employee growth, exchange listings and data sources
- Name: Genetic Signatures Limited
- Ticker: GSS
- Exchange: ASX
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$143.390m
- Shares outstanding: 143.39m
- Website: https://www.geneticsignatures.com
- Genetic Signatures Limited
- 7 Eliza Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.